Datasheet for ABIN988172

# CXCL7 Protein

Go to Product page

## Overview

| | |
|---|---|
| Quantity: | 1 mg |
| Target: | CXCL7 (PPBP) |
| Origin: | Human |
| Source: | Escherichia coli (E. coli) |
| Biological Activity: | Active |

## Product Details

| | |
|---|---|
| Sequence: | AELRCMCIKT TSGIHPKNIQ SLEVIGKGTH CNQVEVIATL KDGRKICLDP DAPRIKKIVQ KKLAGDESA |
| Characteristics: | Fully biologically active when compared to standard. The ED50 determined by a chemotaxis bioassay using human peripheral blood neutrophils is less than 10 ng/ml, corresponding to a specific activity of >, 1.0 × 105 IU/mg. |
| Purity: | > 97 % by SDS-PAGE and HPLC analyses. |
| Endotoxin Level: | Level Less than 1EU/μg of rHuNAP-2/CXCL7 as determined by LAL method |

## Target Details

| | |
|---|---|
| Target: | CXCL7 (PPBP) |
| Alternative Name: | NAP-2 /CXCL7 (PPBP Products) |
| Background: | Neutrophil Activating Peptide 2 (NAP-2) is proteolytically processed carboxyl-terminal fragments of platelet basic protein (PBP) which is found in the alpha-granules of human platelets. NAP-2 is a member of the CXC chemokines. Similar to other ELR domain containing |

## Target Details

| | |
|---|---|
| | CXC chemokines such as IL-8 and the GRO proteins, NAP-2 has been shown to bind CXCR-2 and to chemoattract and activate neutrophils. Although CTAP-III, beta-TG and PBP represent amino-terminal extended variants of NAP-2 and possess the same CXC chemokine domains, these proteins do not exhibit NAP-2 activity. Recently, it has been shown that the additional amino-terminal residues of CTAP-III masks the critical ELR receptor binding domain that is exposed on NAP-2 and may account for lack of NAP-2 activity. Synonym: NAP-2 /CXCL7, Human. Formulation: Lyophilized from a 0.2µm filtered concentrated solution in 20mM PB, pH 7.4, 50mM NaCl. |
| Molecular Weight: | 7.6 kDa, a single non-glycosylated polypeptide chain containing 70 amino acids. |

## Application Details

| | |
|---|---|
| Restrictions: | For Research Use only |

## Handling

| | |
|---|---|
| Format: | Lyophilized |
| Reconstitution: | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at < -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage: | 4 °C |